Product Reports Resources Pricing Login Book a demo

Evotec

Biotech & Life Sciences · Hamburg, Germany · Founded 1993 · IPO 2012

Drug discovery and development for pharma and biotech

Valuation $610M
Revenue $660M

Investors

5 investors on Evotec's cap table

Sourced from Dealroom's funding history.

Series B+ 5 investors entered at this stage
3i Group
Max Planck Innovation
Max Planck Society
Gilde Healthcare
Max Planck Institute for the Structure and Dynamics of Matter

Global footprint

Where Evotec has talent and traffic

Workforce by country
25 countries with
team presence
🇩🇪 Germany27.9%
🇫🇷 France27.5%
🇮🇹 Italy19.3%
🇬🇧 United Kingdom18.3%
🇺🇸 United States4.8%
Top 5 of 25 shown
Web traffic by country
110K monthly visits
across markets
🇺🇸 United States15%
🇹🇷 Turkey11.7%
🇩🇪 Germany10.5%
🇬🇧 United Kingdom9.8%
🇩🇰 Denmark7.4%
Top 5 markets shown

Talent graph

The shape of Evotec's talent

Dealroom maps Evotec's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

47 standout operatorsDealroom-flagged across the org
97 AI specialistsincl. 33 core researchers
4,749 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Evotec's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$43M patent portfolio · 63 active families

Estimated portfolio value
$43M
7.0% of market cap · 9.6× smaller than top peer Supernus Pharmaceuticals ($413M)
63 active patent families
Where Evotec innovates DiseaseDisease causeDisease injuryDrugInflammation

Where Evotec concentrates vs peers

Each axis is a top-10 topic across Evotec and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Evotec's 38 investments and acquisitions.

Every disclosed deal where Evotec appeared as a backer or acquirer, 2000–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

38 deals across Evotec's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Evotec's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        38 of 38 deals

        Market sentiment

        What the market is saying about Evotec

        An AI-synthesized read of the highest-engagement posts about Evotec on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Evotec on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.